Harmony Corp (HRMY) Kelajakdagi narxning foydaga nisbati

harmonybiosciences.com (HRMY) grafik logotipi

Harmony Biosciences neyrofarmatsevtika sohasidagi nufuzli brend bo'lib, uning inqirozlarga chidamliligi terapiyaga bo'lgan o'tkir bemorlar ehtiyoji bilan mustahkamlanadi. GURU.Markets platformasida emitentning kutilayotgan P/E ko'rsatkichi baholash dinamikasini namoyish etadi, bunda parametr 8.30 hisoblanadi. Harmony Biosciences moliyaviy muvaffaqiyati haddan tashqari uyquchanlik va narkolepsiya uchun noyob dori vositasining tijoratlashtirilganiga asoslangan bo'lib, bu barqaror foyda o'sishini ta'minlaydi.

Prognoz qilingan narxning foydaga nisbati: Harmony Biosciences Holdings, Inc. (HRMY) 04.07.2022 - 17.11.2026 uchun

Harmony Biosciences Holdings, Inc. (HRMY) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

Kompaniyaning barcha koʻrsatkichlari tahlili:Harmony Pharma HRMY
harmonybiosciences.com brend mahsuloti

Harmony Biosciences (HRMY) moliyaviy barqarorligini baholash uchun biznes qiymatini kutilayotgan daromadlar bilan nisbatda tahlil qilish juda muhimdir. Forward P/E koeffitsiyenti joriy bozor kapitalizatsiyasini kelgusi yil uchun taxminiy daromadlar bilan solishtiradi. Harmony Biosciences (HRMY) uchun 12 oylik forward P/E tendentsiyasi dori vositasining nevrologiya segmentidagi kengayishiga oid bozor kutganlarini aks ettiradi. Ushbu ko'rsatkich B2B klinikalaridan tushadigan daromadlar o'sish sur'atlariga tabiiy ravishda sezgir hisoblanadi. Agar SOM barqaror qolsa, past metrika qiymatlari aktivning qadrini past baholanganligidan dalolat beradi.

Toʻgʻridan-toʻgʻri raqobatchilar

Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori RGC (Regencell Bioscience Ltd)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Kelajakdagi narxning foydaga nisbati|Supernus Corp - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati CPRX|Denali Therapeutics Inc. (DNLI) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Forvard P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Narxning kutilayotgan foydaga nisbati|anavex.com - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori CBLL (CeriBell, Inc.)|PRTA: Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ALEC|ANNX (Annexon Biosciences Inc.) - Forvard P/E multiplikatori|omeros.com - Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Neurogene (NGNE)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AC Immune SA|Forvard P/E multiplikatori VYGR (voyagertherapeutics.com)|Forvard P/E multiplikatori Neumora NMRA|Scilex Holding - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Kelajakdagi narxning foydaga nisbati|cogrx.com (CGTX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Assertio Therapeutics (ASRT)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Coya|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)